Location Directory

Clinical trials in San Francisco, California

This page shows live ClinicalTrials.gov search results for San Francisco, California, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:24 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

5126

Shown on this page

Current sort

Institutions in San Francisco

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

UCSF

Live official records

Open in full search

Conditions: Mitral Valve Regurgitation
Interventions: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR); Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2036
U.S. locations: 78
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 57 more

Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions: Adagrasib, Pembrolizumab; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 220
States / cities: Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more

Conditions: Pregnancy Preterm, Premature Birth, Pregnancy Complications, Obstetric Labor, Premature, Obstetric Labor Complications
Interventions: Periviable GOALS DST; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 12
States / cities: San Diego, California • San Francisco, California • New Haven, Connecticut + 9 more

Conditions: Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
Interventions: pembrolizumab, placebo, cisplatin, 5-FU, radiotherapy, leucovorin, levoleucovorin, oxaliplatin; Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 703 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 19
States / cities: Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more

Conditions: Hepatocellular Carcinoma
Interventions: TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 12
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more

Conditions: Mesial Temporal Lobe Epilepsy
Interventions: NRTX-1001, Sham Comparator; Biological · Procedure
Lead sponsor: Neurona Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2043
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer, Endometrial Cancer, Mismatch Repair Deficient or MSI-High Solid Tumors
Interventions: EIK1005, pembrolizumab (KEYTRUDA® ); Drug
Lead sponsor: Eikon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Doral, Florida • Hialeah, Florida + 7 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 17
States / cities: Oakland, California • Roseville, California • San Francisco, California + 13 more

Conditions: Myocardial Infarction
Interventions: i-STAT hs-TnI Cartridge Testing on i-STAT 1 and i-STAT Alinity; Diagnostic Test
Lead sponsor: Abbott Point of Care; Industry
Eligibility: 18 Years and older
Enrollment: 3,697 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 28
States / cities: Chandler, Arizona • San Francisco, California • Stanford, California + 25 more

Conditions: Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Interventions: Maridebart Cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 45 Years to 99 Years
Enrollment: 12,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 140
States / cities: Daphne, Alabama • Fairhope, Alabama • Huntsville, Alabama + 117 more

Conditions: Inherited Retinal Degeneration, Retinitis Pigmentosa
Interventions: Not listed
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 4 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 19
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more

Conditions: Aortic Valve Regurgitation, Aortic Valve Disease Mixed
Interventions: J-Valve Transfemoral (TF) System; Device
Lead sponsor: JC Medical, Inc., an affiliate of Edwards Lifesciences LLC; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 35
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more

Clinical trials in San Francisco, California

Filter and sort this location

Institutions in San Francisco

Live official records

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Periviable GOALS Decision Support Tool

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

TheraSphere With Durvalumab and Tremelimumab for HCC

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Abbott i-STAT High Sensitivity Troponin I Study

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

J-Valve Transfemoral Pivotal Study